Olaparib plus ceralasertib may benefit pediatric cancer patients with DNA-repair-deficient tumors
A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical benefit in pediatric patients with solid tumors exhibiting DNA replication stress and/or DNA repair ...
Apr 18, 2023
0
9